

REMARKS

Present Status of the Application

Claims 1-9 and 33-47 remain pending. The Final Office Action dated May 14, 2009 objected claim 2 for informalities. Claims 1-2, 7 and 39-42 were rejected under 35 U.S.C. 112, first paragraph for new matters and for enablement requirement. Claims 1-3, 7 and 39-42 were rejected under 35 U.S.C. 112, second paragraph as being indefinite.

Claims 1-2 have been cancelled, while claim 3 has been amended as an independent claim. Claims 3, 7 and 39 have been amended to correct dependency. Accordingly, among the withdrawn claims 46, 8-9, 33-38 and 43-47, claims 4, 9, 33, 43, 45 and 47 have been amended to correct dependency as well. It is believed that no new matters are added for the amendments and entry of the amendments is respectfully requested. After entering the amendments and considering the following discussions, a notice of allowance is respectfully solicited.

Discussion of objection

Claim 2 was objected for informalities.

Claim 2 has been cancelled.

Withdrawal of this objection is earnest requested.

Discussion of 112 rejections

Claims 1-2, 7 and 39-42 were rejected under 35 U.S.C. 112, first paragraph for new matters.

Claims 1-2 have been cancelled.

Withdrawal of this 112 rejection is respectfully requested.

Claims 1-3, 7 and 39-42 were rejected under 35 U.S.C. 112, second paragraph as being indefinite.

Claims 1-2 have been cancelled. Claim 3 has been amended as an independent claim. Claims 7 and 39-42 have been amended accordingly to be dependent upon claim 3 or to recite claim 3.

Withdrawal of this 112 rejection is respectfully requested.

Claims 1-2, 7 and 39-42 were rejected under 35 U.S.C. 112, first paragraph as the specification does not provide enablement for the peptides having generic peptide formulas (S-I) or (S-II) set forth in claim 1.

Claims 1-2 have been cancelled.

Claim 3 has been amended as an independent claim. Claims 7 and 39-42 have been amended accordingly to be dependent upon claim 3 or to recite claim 3.

As admitted by the Office Action, the specification of the present invention already “enable the isolated cysteine-containing peptides set forth in claim 3” (page 4 of Office Action).

Therefore, the 112 objections for enablement directing to claim 1 or 2 are moot.

Accordingly, withdrawal and reconsideration of these 112 rejections are respectfully requested.

CONCLUSION

For at least the foregoing reasons, it is believed that the pending claims 3, 7 and 39-42 of the present application patently defines over the prior art and are in proper condition for allowance. If the Examiner believes that a telephone conference would expedite the examination of the above-identified patent application, the Examiner is invited to call the undersigned.

Respectfully submitted,
J.C. PATENTS

Date: August 10, 2009

/JIAWEI HUANG/
Jiawei Huang
Registration No. 43,330

4 Venture, Suite 250
Irvine, CA 92618
Tel.: (949) 660-0761
Fax: (949)-660-0809